Single cell antibody discovery using 'Islands of Automation'

Eli Lilly, a global healthcare leader, has implemented a next generation research (NGR) initiative to improve the value output of the R&D portfolio. One of the NGR pillars focuses on decreasing the timeline to bring medicines to patients. Lilly has invested in ‘Islands of Automation’ to advance the B cell antibody discovery platform at the Lilly Biotechnology Center in San Diego with the goal of significantly increasing throughput and reducing project timelines.

 

In this webinar, Paul Anderson, Director - Biologics Discovery Automation at Eli Lilly will focus on the automated systems that have been developed as part of this platform. This highly automated approach to antibody discovery has enabled Lilly to meet aggressive timelines and dramatically increase throughput while allowing flexibility for future changes to its process.

 

Learning Objectives